ArticleAmerican journal of blood research2026

Venetoclax-based low-intensity therapy in pediatric AML: A viable option for chemotherapy-intolerant patients.

Nidhi Dhariwal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.